Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Caldeira

Pcn326 - Comparative Analysis of Esmo Magnitude of Clinical Benefit Scale Values Assigned to NSCLC Cancer Drugs, Versus Real World Data on Prescribing Activity and Levels of Satisfaction in the Eu5

Value in Health

English

Corrigendum to “The 2014–15 Eruption and the Short-Term Geochemical Evolution of the Fogo Volcano (Cape Verde): Evidence for Small-Scale Mantle Heterogeneity” [Lithos 288–289 (2017) 91–107]

English

Related publications

ESMO - Magnitude of Clinical Benefit Scale V.1.0 Questions and Answers

English

Detailed Statistical Assessment of the Characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) Threshold Rules

English

THU0503 Cost Analysis of Anti-Osteoporotic Drugs in Real-World Clinical Practice

2018

English

Analysis of Real World Data to Evaluate Survival Benefit of Radiation Therapy in Stage III / N2 Non-Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics

English

P3.01-106 Real-World Data to Evaluate the Clinical Benefit of NGS for Directing Lung Adenocarcinoma Treatment

Journal of Thoracic Oncology

English

The Risk/Benefit Profile of Biologic Drugs in Real-World Rheumatology Practice. From ANTARES to MonitorNet

Reumatismo

Rheumatology

2011

English

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology

English

MS26.02 Translation of Clinical Data to Real World - North America

Journal of Thoracic Oncology

English

THU0474 Utilisation of Anti-Osteoporotic Drugs in Real-World Data: An Analysis of Persistence to Therapy and Risk of Fracture

2018

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Caldeira

Pcn326 - Comparative Analysis of Esmo Magnitude of Clinical Benefit Scale Values Assigned to NSCLC Cancer Drugs, Versus Real World Data on Prescribing Activity and Levels of Satisfaction in the Eu5

Corrigendum to “The 2014–15 Eruption and the Short-Term Geochemical Evolution of the Fogo Volcano (Cape Verde): Evidence for Small-Scale Mantle Heterogeneity” [Lithos 288–289 (2017) 91–107]

Related publications

ESMO - Magnitude of Clinical Benefit Scale V.1.0 Questions and Answers

Detailed Statistical Assessment of the Characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) Threshold Rules

THU0503 Cost Analysis of Anti-Osteoporotic Drugs in Real-World Clinical Practice

Analysis of Real World Data to Evaluate Survival Benefit of Radiation Therapy in Stage III / N2 Non-Small Cell Lung Cancer

P3.01-106 Real-World Data to Evaluate the Clinical Benefit of NGS for Directing Lung Adenocarcinoma Treatment

The Risk/Benefit Profile of Biologic Drugs in Real-World Rheumatology Practice. From ANTARES to MonitorNet

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

MS26.02 Translation of Clinical Data to Real World - North America

THU0474 Utilisation of Anti-Osteoporotic Drugs in Real-World Data: An Analysis of Persistence to Therapy and Risk of Fracture